These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32723847)

  • 1. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
    Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
    J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
    Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
    Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and Prediction of Organic Anion Transporting Polypeptide 1B Activity in Prostate Cancer Patients on Abiraterone Acetate Using Endogenous Biomarker Coproporphyrin I.
    Wang Z; Luk KHY; Cheong EJY; Tham SM; Periaswami R; Toh PC; Wang Z; Wu QH; Tsang WC; Kesavan A; Wong ASC; Wong PT; Lim F; Chiong E; Chan ECY
    Drug Metab Dispos; 2024 Oct; 52(11):1356-1362. PubMed ID: 39187385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
    Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
    Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
    Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
    Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
    Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
    J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe.
    Kinzi J; Grube M; Seibert I; Siegmund W; Meyer Zu Schwabedissen HE
    Clin Transl Sci; 2024 Oct; 17(10):e70041. PubMed ID: 39382439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
    Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
    Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Probenecid on Hepatic and Renal Disposition of Hexadecanedioate, an Endogenous Substrate of Organic Anion Transporting Polypeptide 1B in Rats.
    Futatsugi A; Masuo Y; Kato Y
    J Pharm Sci; 2021 May; 110(5):2274-2284. PubMed ID: 33607188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
    Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
    Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
    Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
    Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
    Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
    J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
    Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
    Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
    Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
    Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
    Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study.
    Kikuchi R; Qian Y; Badawi M; Savaryn JP; Gannu S; Eldred A; Hao S; Salem AH; Liu W; Klein CE; Mohamed MF
    Clin Pharmacol Ther; 2024 Nov; 116(5):1334-1342. PubMed ID: 39102854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.